Stay updated on Risdiplam in SMA Type 2/3: Clinical Trial
Sign up to get notified when there's something new on the Risdiplam in SMA Type 2/3: Clinical Trial page.

Latest updates to the Risdiplam in SMA Type 2/3: Clinical Trial page
- Check4 days agoChange DetectedA general NIH website-transition notice appears above the 403 error message. The site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe footer now displays site revision v3.7.1 instead of v3.7.0 on the 403 Forbidden page.SummaryDifference0.2%

- Check32 days agoChange DetectedThe study page now displays a 403 Forbidden error (with a minimal header and a Home link) instead of the full study record content for NCT02908685. This indicates blocked access rather than the usual display of the study details.SummaryDifference20%

- Check39 days agoChange DetectedA new page revision label, v3.7.0, was added and the previous revision label, v3.6.6, was removed, indicating the page has been updated to a newer version.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page revision was updated from v3.6.5 to v3.6.6, indicating a minor editorial update to the study page.SummaryDifference0.0%

- Check60 days agoChange DetectedA line indicating NIH funding/contract information was added to the study's identifiers, clarifying the funding source and associated numbers.SummaryDifference0.0%

Stay in the know with updates to Risdiplam in SMA Type 2/3: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risdiplam in SMA Type 2/3: Clinical Trial page.